logo
ProjectPlanned

Fermentation-Based 7-ACA Facility

Sector: Manufacturing (Industrial) • Location: Kathua, Jammu & Kashmir, India

Source: IndiaMedToday

Orchid Pharma is setting up India’s first biotechnology fermentation-based facility for 7-Amino Cephalosporanic Acid (7-ACA) with an investment of about ₹600 crore in Kathua, Jammu & Kashmir. The plant will produce 7-ACA, a core key starting material for cephalosporin antibiotics, through fermentation technology to strengthen domestic antibiotic supply chain and reduce import dependency.

Status
Prospective
Sector
Manufacturing (Industrial), Warehouse
Location
Kathua, Jammu & Kashmir, India
Updated
22 Jul 2026
Source
IndiaMedToday

ConstructChat

Ask ConstructChat about Fermentation-Based 7-ACA Facility

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “Fermentation-Based 7-ACA Facility” is an infrastructure initiative in the Manufacturing (Industrial) sector, located in Kathua, Jammu & Kashmir, India. Taiyo aggregates data on it from IndiaMedToday.

Participants

Not available for this record.

Status

Original status

planned

Taiyo status

Prospective

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Orchid Pharma is setting up India’s first biotechnology fermentation-based facility for 7-Amino Cephalosporanic Acid (7-ACA) with an investment of about ₹600 crore in Kathua, Jammu & Kashmir. The plant will produce 7-ACA, a core key starting material for cephalosporin antibiotics, through fermentation technology to strengthen domestic antibiotic supply chain and reduce import dependency.

Original sector

Pharmaceutical Manufacturing

Budget

Location

Country

India

State

Jammu & Kashmir

City

Kathua

Source

Source

IndiaMedToday

URL

More Details

Record type

Project

Sector

Manufacturing (Industrial), Warehouse

Article published date

2026-03-20

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project